Department of Medicine, Toronto, ON, Canada; Department of Health Policy, Management, and Evaluation, Toronto, ON, Canada; Department of Medicine, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Department of Medicine, Toronto, ON, Canada; Department of Health Policy, Management, and Evaluation, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada.
Chest. 2012 Feb;141(2):348-353. doi: 10.1378/chest.11-0426. Epub 2011 Aug 18.
Animal and human studies suggest that selective serotonin reuptake inhibitors (SSRIs) might be useful for the prevention or treatment of pulmonary arterial hypertension.
We conducted a population-based, nested case-control study to explore the hypothesis that SSRIs might reduce the risk of pulmonary arterial hypertension. Cases were individuals who developed pulmonary arterial hypertension requiring pharmacologic treatment. For each case, we selected up to 10 matched control subjects. Exposure to SSRIs and non-SSRI antidepressants was ascertained using administrative data. The outcome of pulmonary arterial hypertension requiring pharmacologic therapy was defined as the receipt of a drug specific for the treatment of pulmonary arterial hypertension.
In contrast to our hypothesis, and likely because of residual confounding, we found a positive association between SSRI use and pulmonary arterial hypertension (adjusted OR, 1.55; 95% CI, 1.13-2.13).
At conventional doses, SSRIs are not associated with a reduced risk of pulmonary arterial hypertension.
动物和人体研究表明，选择性 5-羟色胺再摄取抑制剂（SSRIs）可能有助于预防或治疗肺动脉高压。
我们进行了一项基于人群的巢式病例对照研究，以探讨 SSRIs 可能降低肺动脉高压风险的假设。病例为需要药物治疗的肺动脉高压患者。对于每个病例，我们选择最多 10 名匹配的对照。使用行政数据确定 SSRIs 和非 SSRIs 抗抑郁药的暴露情况。需要药物治疗的肺动脉高压的结果定义为接受特定于肺动脉高压治疗的药物。
与我们的假设相反，可能是由于残留混杂因素，我们发现 SSRIs 使用与肺动脉高压之间存在正相关（调整后的 OR，1.55；95%CI，1.13-2.13）。
在常规剂量下，SSRIs 与降低肺动脉高压风险无关。
